To boost its oncology portfolio, Lilly has agreed to acquire Scorpion Therapeutics and its PI3Kα inhibitor programme in a deal worth up to US$2.5 B. Through this deal, Lilly will gain access to Scorpion's lead product, STX-478, which is a once-daily, oral, mutant-selective PI3Kα inhibitor, that is currently being evaluated in a Phase I/II clinical trial for breast cancer and other advanced solid tumours. As part of the deal, Scorpion will create a new company to handle its non-PI3Kα pipeline assets.